The important role of both C3 and C5a in lung cancer progression as shown by elegant studies using mouse models of NSCLC [144, 145] and the additive effect of complement inhibition in tumour progression [146] has provided strong evidence for complement related anti-tumour effect, thus possibly opening new therapeutic avenues. This evidence concerns the gene C5 and non-small cell lung carcinoma.